358 related articles for article (PubMed ID: 12501885)
1. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
2. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Shorr AF; Ramage AS
Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States.
Caprini JA; Botteman MF; Stephens JM; Nadipelli V; Ewing MM; Brandt S; Pashos CL; Cohen AT
Value Health; 2003; 6(1):59-74. PubMed ID: 12535239
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
Hawkins DW; Langley PC; Krueger KP
Clin Ther; 1998; 20(1):182-95. PubMed ID: 9522114
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.
Levin LA; Bergqvist D
Pharmacoeconomics; 2001; 19(5 Pt 2):589-97. PubMed ID: 11465303
[TBL] [Abstract][Full Text] [Related]
8. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
10. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
11. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
12. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
13. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
14. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
Hawkins DW; Langley PC; Krueger KP
Am J Health Syst Pharm; 1997 May; 54(10):1185-90. PubMed ID: 9161627
[TBL] [Abstract][Full Text] [Related]
17. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
Garcia-Zozaya I
J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Yan X; Gu X; Xu Z; Lin H; Wu B
Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
[TBL] [Abstract][Full Text] [Related]
19. A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.
Bao Y; Zhao G; Qu S; Xiong T; Yao X; Wu B
Clin Drug Investig; 2020 Feb; 40(2):161-171. PubMed ID: 31773492
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]